Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Celgene Corporation : Celgene Outlines Plan for New Growth Phase

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/07/2013 | 05:44pm EDT

--Celgene expects to double net product sales between 2013 and 2017

--Company outlines numerous milestones in 2013 for three "potential blockbuster" drugs

--Two late-stage trials for experimental psoriasis drug apremilast meet primary goals

(Updates with analyst comment in paragraph 10, updated stock price in paragraph 15.)

 
   By Joseph Walker 
 

Celgene Corp. (CELG) detailed its strategy to achieve $12 billion in product sales by 2017, twice what it expects this year, as it expands its core hematology franchise and builds out new product lines in cancer and psoriasis.

"We absolutely believe that the best days of Celgene are in front of us," Chief Executive Robert Hugin said at the J.P. Morgan Healthcare Conference in San Francisco. "We have the opportunity to accelerate growth, build out these new franchises and have great results over the next five years."

Mr. Hugin said Celgene has three "potential blockbusters" that will face key milestones this year, including an application to the Food and Drug Administration for its Abraxane to treat pancreatic cancer, one of the hardest-to-treat cancers. The drug is already approved in other types of cancer.

The company also expects to seek regulatory approval in the second half of this year for its experimental drug apremilast to treat psoriasis, the severe skin rash disease. The drug met its primary goals in two late-stage studies, the company said Monday.

For 2012, the biopharmaceutical company said it now expects adjusted earnings of $4.90 a share and revenue of $5.5 billion, at the high end of its previous view of $4.85 to $4.90 a share and $5.45 billion to $5.55 billion, respectively.

Fourth-quarter and full-year results will be released Jan. 24.

The Summit, N.J., firm is a leader in treating blood cancer, and its hallmark drug Revlimid surpassed $1 billion in sales in the fourth quarter, the first time it has reached that mark in a single quarter, Mr. Hugin said. The company hopes to receive new approvals for Revlimid in the U.S., Europe and China this year.

The company's experimental drug Pomalyst could be the company's "next blockbuster," Mr. Hugin said, with a U.S. regulatory approval decision expected "in the next month or so" and in Europe by the end of 2013 to treat relapses of multiple myeloma.

For the new year, Celgene forecast adjusted earnings of $5.50 to $5.60 a share, in line with expectations of $5.56 from analysts polled by Thomson Reuters. It also predicted product sales, which account for nearly all the company's revenue, of $6 billion. Analysts project total revenue of $6.05 billion.

"We believe Celgene is re-emerging as a clean, earnings-driven growth stock as Abraxane's potential in pancreatic cancer becomes more fully appreciated and Revlimid gets back on track with European regulators," said Eric Schmidt, a Cowen & Co. analyst. "We expect Celgene's stock multiple to expand as a result."

Celgene expects Revlimid sales in 2013 to range from $4.1 billion to $4.2 billion, up about 9% to 12% year over year.

The company also reaffirmed its long-term financial targets for 2015 and forecast $13 to $14 a share in adjusted earnings and $12 billion in product sales for 2017.

Like other big drug makers, Celgene has been striving to find new treatments, as well as expand the uses of older ones, to drive growth. The company has been trying to expand uses of its blood-cancer treatment Revlimid to new diseases such as newly diagnosed multiple myeloma as well as non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

In October, the company said its third-quarter profit rose as it continued to see strong growth in Revlimid.

Celgene shares rose 4.4% to $85.73 on Monday. The stock is up 3.1% over the past three months.

-Ben Fox Rubin contributed to this article.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
03/19If This Is Failure, Show Me Success -- Overheard
DJ
03/15BRISTOL MYERS SQUIBB : Mutual funds start to put their mouth where their money i..
RE
03/14Citi dealmaker says mergers and acquisitions to slow down
RE
03/13CELGENE : Provides Update on ABRAXANE Combination Therapy in the Treatment of Me..
AQ
03/12CELGENE : Provides Update on ABRAXANE® Combination Therapy in the Treatment of M..
BU
03/11CELGENE : Submits Application to EMA for Ozanimod for the Treatment of Relapsing..
BU
03/08CELGENE CORP /DE/ : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
03/08CELGENE : DE/ Financial Statements and Exhibits (form 8-K/A)
AQ
03/06BRISTOL MYERS SQUIBB : Myers defends Celgene bet as investor criticism grows
RE
03/05Celgene Gets FDA Priority Review for Fedratinib in Myelofibrosis
DJ
More news
Financials ($)
Sales 2019 17 116 M
EBIT 2019 9 833 M
Net income 2019 6 155 M
Debt 2019 7 342 M
Yield 2019 -
P/E ratio 2019 10,25
P/E ratio 2020 8,69
EV / Sales 2019 4,11x
EV / Sales 2020 3,38x
Capitalization 62 952 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 97,7 $
Spread / Average Target 9,0%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION39.85%62 952
JOHNSON & JOHNSON7.01%367 729
NOVARTIS10.85%239 412
PFIZER-2.98%235 119
ROCHE HOLDING LTD.11.20%234 784
MERCK AND COMPANY8.56%214 112